Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2009-03-18
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving RAV12 together with gemcitabine may kill more
tumor cells.
PURPOSE: This phase II trial is studying the side effects and best dose of monoclonal
antibody RAV12 when given together with gemcitabine in treating patients with metastatic
pancreatic cancer.